Case Study on Azithromycin in Pharmamarket

This case analysis delves into the position of azithromycin in the international pharmaceutical market, tracing its evolution, marketplace dynamics, and challenges over the years. Registered in the early 1990s, azithromycin transformed the course of bacterial infections treatment with its broad-spectrum activity, abbreviated duration of therapy, and improved side-effect profile. The marketplace success of the drug was fuelled by the convenience of treatment, which ranked it as the preferred antibiotic both among healthcare practitioners and patients. Nevertheless, its market trajectory changed with the expiration of its patent in 2005, which led to the widespread availability of generics, whose effect on its pricing and market share was significantly adverse. Moreover, azithromycin also attracted attention following the COVID-19 pandemic when it was researched as a possible treatment for the disease despite the subsequent trials discrediting its efficacy for the same. This case study shows how critical azithromycin has been to dealing with global health issues, specifically in poor parts of the world, where generics have widened treatment access. It also tackles newer issues such as antibiotic resistance and changing regulations. The conclusion is that the success of GlaxoSmithKline underscores the challenges of balancing competitiveness in the pharmaceutical business while meeting public health demands and shifting treatment approaches.